New Novartis AG Chairman Reviews Portfolio, Fueling Speculation That Company May be Splitting Up

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis may take a leaf out of its past deal-book as the Swiss drugmaker conducts a review into some of its underperforming businesses, a board member said.

New chairman Joerg Reinhardt has launched a review of the drugmaker's portfolio fanning speculation that some of the company's smaller units could be sold, spun-off or integrated into other divisions.

Help employers find you! Check out all the jobs and post your resume.

Back to news